Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8:12:1315-1335.
doi: 10.2147/JHC.S528470. eCollection 2025.

Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps

Collaborators, Affiliations

Multidisciplinary Team Management of Hepatocellular Carcinoma in the MENA Region: Current Practices, Challenges, and Gaps

Mohamed El-Kassas et al. J Hepatocell Carcinoma. .

Abstract

Purpose: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a high disease burden in the Middle East and North Africa (MENA) region. Multidisciplinary teams (MDTs) are essential for optimizing HCC management; however, their implementation and impact may vary across healthcare settings. This study evaluates the structure, decision-making processes, and challenges faced by MDTs in HCC treatment centers across the MENA region.

Patients and methods: This cross-sectional, multicenter study surveyed representatives from 53 HCC treatment centers across 38 cities in 11 MENA countries. A structured questionnaire was electronically distributed to assess MDT composition, meeting frequency, decision-making processes, adherence to clinical guidelines, patient management pathways, and challenges in HCC treatment.

Results: Among the surveyed centers, 84.9% (n=45) reported having an established MDT. The most common specialties involved in MDT composition were hepatology (100%), interventional radiology (97.8%), medical oncology (91.1%), and hepatobiliary surgery (80%). Barcelona Clinic Liver Cancer staging was used in 95.6% of centers. Despite acknowledging MDT benefits, major challenges were documented by participants, including resource limitations (13.2%), financial constraints (13.2%), patient nonadherence (9.4%), and limited access to advanced technology (11.3%). Telemedicine was underutilized (9.4% of centers), and only 15.1% experienced participation in clinical trials.

Conclusion: Our result highlights the pivotal role of MDTs in HCC management in the MENA region, demonstrating adherence to evidence-based guidelines and exposing critical gaps in resource availability, technology integration, and patient-centered decision-making. Strengthening MDTs through enhanced resource allocation, digital health adoption, and increased clinical trial participation is essential to improving HCC outcomes in the region.

Keywords: MENA region; cancer management; clinical decision-making; hepatocellular carcinoma; multidisciplinary team.

Plain language summary

This study identifies critical gaps in multidisciplinary hepatocellular carcinoma (HCC) management across the Middle East and North Africa (MENA). Despite recognizing multidisciplinary teams’ value, inconsistent implementation, fragmented referral pathways, limited diagnostic tool accessibility, and insufficient public awareness significantly hinder optimal patient care. Addressing these gaps urgently requires integrated national policies, expanded diagnostic infrastructure, enhanced clinician training, structured referral systems, and stronger public and patient engagement strategies. The study underscores the necessity for a strategic, coordinated approach to improve clinical outcomes and reduce the healthcare burden of HCC in the region.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Strategies to improve the MDT processes at the HCC treatment centers in the MENA region.

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2024;74(3):229–263. doi: 10.3322/caac.21834 - DOI - PubMed
    1. Rumgay H, Ferlay J, de Martel C, et al. Global, regional, and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108–118. doi: 10.1016/j.ejca.2021.11.023 - DOI - PubMed
    1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–90. doi: 10.1016/S2214-109X(19)30488-7 - DOI - PubMed
    1. Thomas London W, Petrick JL, McGlynn KA. Cancer epidemiology and prevention. 2018;635–660.
    1. Kamal S. Hepatocellular carcinoma in the Middle East: an overview. Liver Cancer Middle East. 2021;299–311.